Huperzine A vs NSI-189

Mechanism

Potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), derived from the club moss Huperzia serrata. Exhibits preference for the tetrameric G4 form of AChE predominant in the mammalian brain. Eight-fold more potent than donepezil and two-fold more potent than rivastigmine at AChE inhibition. Crosses the BBB efficiently. Also antagonizes NMDA receptors at high concentrations and provides neuroprotection via attenuation of oxidative stress, regulation of apoptotic proteins (Bcl-2, Bax, P53, caspase-3), and upregulation of NGF.

Standard Dosing

50-200 mcg twice daily

Timing

Morning and early afternoon. With or without food.

Cycle Duration

Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation

Side Effects

• Nausea
• Diarrhea
• Sweating
• Blurred vision
• Muscle twitching
• Bradycardia at high doses

Contraindications

• Bradycardia
• Asthma/COPD (cholinergic bronchoconstriction)
• GI obstruction
• Concurrent use of prescription AChE inhibitors
• Peptic ulcer disease

Best Stacking Partners

Mechanism

Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.

Standard Dosing

40 mg once daily (for educational context — investigational compound, not approved for any indication)

Timing

Once daily, time of day not definitively established from clinical data. With or without food.

Cycle Duration

Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.

Side Effects

• Headache
• GI discomfort
• Dizziness
• Somnolence
• Dry mouth
• Generally well-tolerated in Phase 1b and Phase 2 trials

Contraindications

• Pregnancy and lactation (no safety data; neurogenic compounds carry theoretical teratogenic risk)
• History of brain tumors (neurogenic stimulation could theoretically promote growth — speculative)
• No regulatory approval for any indication — investigational use only

Best Stacking Partners